Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naïve Adults

(2020) James E Moon et al.   JOURNAL OF INFECTIOUS DISEASES

First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria

(2019) Benjamin Mordmüller et al.   CLINICAL INFECTIOUS DISEASES

A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein

(2018) Joshua Tan et al.   NATURE MEDICINE

A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite

(2018) Neville K Kisalu et al.   NATURE MEDICINE

Proteolytic Cleavage of thePlasmodium falciparumCircumsporozoite Protein Is a Target of Protective Antibodies

(2015) Diego A. Espinosa et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

(2015) Michael T White et al.   LANCET INFECTIOUS DISEASES

A Full-Length Plasmodium falciparum Recombinant Circumsporozoite Protein Expressed by Pseudomonas fluorescens Platform as a Malaria Vaccine Candidate

(2014) Amy R. Noe et al.   PLoS One

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

(2011) Rhea N. Coler et al.   PLoS One

Low Prevalence of Antibodies to Preerythrocytic but Not Blood-Stage Plasmodium falciparum Antigens in an Area of Unstable Malaria Transmission Compared to Prevalence in an Area of Stable Malaria Transmission

(2008) G. S. Noland et al.   INFECTION AND IMMUNITY